DBV Technologies

Capital/Financing Update • Jul 1, 2014

Half year update on the DBV Technologies liquidity agreement

Bagneux, France, July 1, 2014 – Under the liquidity agreement signed between DBV TECHNOLOGIES and NATIXIS, the following resources were listed in the liquidity account on June 30th, 2013:

9 018 DBV TECHNOLOGIES' shares 478,300.41€

As a reminder, during the last half year liquidity agreement on December 31th, 2013, the following assets appeared on the liquidity account:

5 253 DBV TECHNOLOGIES' shares ‐ 263,429.63€

About DBV Technologies

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide‐patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www.dbv‐technologies.com

CAUTION: Viaskin® is not approved for sale in the USA.

Viaskin® and EPIT™ are registered trademarks of DBV Technologies, SA

DBV Technologies Contacts David Schilansky Chief Financial Officer Tel. : +33(0)1 55 42 78 75 david.schilansky@dbv‐technologies.com

Susanna Mesa VP Finance, US Investor Relations & Strategy Tel. : +1 917‐346‐3447 susanna.mesa@dbv‐technologies.com

Nathalie Donne

Director Business Development & Corporate Communication Tel. : +33(0)1 55 42 78 72 nathalie.donne@dbv‐technologies.com

DBV IR and Media Contacts

Todd James U.S. Investor Relations The Trout Group Tel. : +1 646‐378‐2926 tjames@troutgroup.com

BMC Communications Media Relations Brad Miles Tel. : +1 646‐513‐3125 brad@bmccommunications.com